Himed and Adva Cera Partner to Scale 3D-Printed Implant Production

Himed, a bioceramic materials producer and contract researcher based in Old Bethpage, New York, has entered a strategic partnership with Adva Cera, a specialist in advanced ceramic additive manufacturing. The collaboration creates a development-to-production pathway for 3D-printed calcium phosphate (CaP) components targeting dental, orthopedic, and spinal applications. Customers working with Himed’s Bioceramics Center of Excellence (BCoE), launched in 2024, can now transition from prototype design to qualified serial production through Adva Cera without requalifying materials or making capital investments in printing infrastructure. The partnership addresses the practical barrier of moving from optimized bioceramic designs to regulatory-grade, large-scale manufacturing.

This deal matters because it directly tackles the qualification and scale-up gap that has historically limited ceramic AM adoption in medical implants. While calcium phosphate’s bioresorbable and osteoconductive properties are well-established, the leap from lab-scale prototypes to production volumes with consistent porosity, lattice geometry, and regulatory documentation has remained a bottleneck. Himed’s BCoE provides materials expertise and design optimization; Adva Cera brings serial production capability. Together, they offer a vertically integrated, US-based alternative to overseas ceramic AM supply chains — a factor gaining weight as medical OEMs prioritize domestic sourcing. The ceramics 3D-printing sector is projected to approach $900 million by 2033, and this partnership positions both companies to capture a share of that growth by lowering the adoption friction for implant manufacturers.

For Himed, the partnership extends its value proposition beyond materials supply and contract R&D into a de facto production pipeline, which could accelerate customer conversion and deepen relationships with medtech startups and established OEMs. The practical test will be whether the combined pathway can deliver consistent part quality across batch runs at the volumes required for orthopedic and spinal programs, where qualification cycles are measured in years, not months. Adva Cera must demonstrate that its production throughput and process control meet the regulatory rigor Himed’s customers expect. If executed, this model could become a template for other materials specialists seeking to bridge the prototype-to-production divide without building their own print farms.